Application of design space optimization strategy to the developmentof LC methods for simultaneous analysis of 18 antiretroviral medicinesand 4 major excipients used in various pharmaceutical formulations
[en] tAs one of the world’s most significant public health challenges in low- and middle-income countries,HIV/AIDS deserves to be treated with appropriate medicines, however which are not spared from coun-terfeiting. For that, we developed screening and specific HPLC methods that can analyze 18 antiretroviralmedicines (ARV) and 4 major excipients. Design of experiments and design space methodology wereinitially applied for 15 ARV and the 4 excipients with prediction thanks to Monte Carlo simulations andfocusing on rapidity and affordability thus using short column and low cost organic solvent (methanol)in gradient mode with 10 mM buffer solutions of ammonium hydrogen carbonate. Two other specificmethods dedicated to ARV in liquid and in solid dosage formulations were also predicted and opti-mized. We checked the ability of one method for the analysis of a fixed-dose combination composedby emtricitabine/tenofovir/efavirenz in tablet formulations. Satisfying validation results were obtainedby applying the total error approach taking into account the accuracy profile as decision tool. Then, thevalidated method was applied to test two samples coded A and B, and claimed to contain the tested ARV.Assay results were satisfying only for sample B.
Research Center/Unit :
Centre Interfacultaire de Recherche du Médicament - CIRM
Application of design space optimization strategy to the developmentof LC methods for simultaneous analysis of 18 antiretroviral medicinesand 4 major excipients used in various pharmaceutical formulations
[1] World Health Organization, 10 facts on HIV/AIDS (updated July 2016): http://www.who.int/features/factfiles/hiv/en/.
[2] World Health Organization, HIV/AIDS Fact sheet (updated July 2016): http://www.who.int/mediacentre/factsheets/fs360/en/.
[3] World Health Organization (WHO): Counterfeit triple antiretroviral combination product (Ginovir 3D) detected in Cote d'Ivoire: Information Exchange System Alert No 110. Geneva: WHO; 2003. QSM/MC/IEA.110.
[4] Ahmad, K., Antidepressants are sold as antiretrovirals in DR Congo. Lancet, 363, 2004, 713.
[6] World Health Organization, Prequalification of Medicines Programme. http://apps.who.int/prequal/info_press/documents/Falsified_ZidolamN_23September2011.pdf.
[7] Debrus, B., Lebrun, P., Mbinze, J.K., Lecomte, F., Ceccato, A., Caliaro, G., Mbay, J.M., Boulanger, B., Marini, R.D., Rozet, E., Hubert, Ph., Innovative high-performance liquid chromatography method development for the screening of 19 antimalarial drugs based on a generic approach, using design of experiments, independent component analysis and design space. J. Chromatogr. A 1218 (2011), 5205–5215.
[8] Mbinze, J.K., Yemoa, A., Lebrun, P., Sacré, P.-Y., Habyalimana, V., Kalenda, N., Bigot, A., Atindehou, E., Hubert, Ph., Marini, R.D., Fighting poor quality medicines: development, transfer and validation of generic HPLC methods for analyzing two WHO recommended antimalarial tablets. Am. J. Anal. Chem. 6 (2015), 127–144.
[9] Lebrun, P., Govaerts, B., Debrus, B., Ceccato, A., Caliaro, G., Hubert, Ph., Boulanger, B., Development of a new predictive modelling technique to find with confidence equivalence zone and design space of chromatographic analytical methods. Chemom. Intell. Lab. Syst. 91 (2008), 4–16.
[10] International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Q8 (R2): Pharmaceutical Development, Aug. 2009. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf.
[11] Hubert, Ph., Nguyen-Huu, J.-J., Boulanger, B., Chapuzet, E., Chiap, P., Cohen, N., Compagnon, P.-A., Dewé, W., Feinberg, M., Lallier, M., Laurentie, M., Mercier, N., Muzard, G., Nivet, C., Valat, L., Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal – part I. J. Pharm. Biomed. Anal. 36 (2004), 579–586.
[12] Hubert, Ph., Nguyen-Huu, J.-J., Boulanger, B., Chapuzet, E., Chiap, P., Cohen, N., Compagnon, P.-A., Dewé, W., Feinberg, M., Lallier, M., Laurentie, M., Mercier, N., Muzard, G., Nivet, C., Valat, L., Rozet, E., Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal – part II. J. Pharm. Biomed. Anal. 45 (2007), 70–81.
[13] Hubert, Ph., Nguyen-Huu, J.-J., Boulanger, B., Chapuzet, E., Cohen, N., Compagnon, P.-A., Dewé, W., Feinberg, M., Laurentie, M., Mercier, N., Muzard, G., Valat, L., Rozet, E., Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal – part III. J. Pharm. Biomed. Anal. 45 (2007), 82–96.
[14] Hubert, Ph., Nguyen-Huu, J.-J., Boulanger, B., Chapuzet, E., Cohen, N., Compagnon, P.-A., Dewé, W., Feinberg, M., Laurentie, M., Mercier, N., Muzard, G., Valat, L., Rozet, E., Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal: part IV – examples of application. J. Pharm. Biomed. Anal. 48 (2008), 760–771.
[15] International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Validation of Analytical Procedures: Text and Methodology Q2 (R1), November 2005. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf.
[16] République du Rwanda, Ministère de la Santé, La liste nationale des médicaments essentiels, 5ème édition, Juillet 2010. http://apps.who.int/medicinedocs/documents/s17569fr/s17569fr.pdf.
[17] Republic of Rwanda, ministry of Health, National List of Essential Medicines for Adults, 6th Edition, 2015. http://moh.gov.rw/fileadmin/templates/Docs/NEML_For_Adults_6th_Edition_2015.pdf.
[18] Republic of Rwanda, Ministry of Health, National List of Essential Medicines for Paediatrics, 1st Edition, 2015. http://moh.gov.rw/fileadmin/templates/Docs/NEML_For_Paediatrics-_1st_Edition-2015.pdf.
[19] Guillarme, D., Nguyen, D., Rudaz, S., Veuthey, J.-L., HPLC calculator v3.0: software for chromatographic performance evaluation and HPLC method transfer. Eur. J. Pharm. Biopharm. 68 (2008), 430–440 https://epgl.unige.ch/labs/fanal/hplc_calculator:en.
[20] R Development Core Team, The R Project for Statistical Computing. http://www.r-project.org/, https://cran.r-project.org/bin/windows/base/old/3.2.2/.
[27] European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), Reflection paper on the use of methyl- and propylparaben as excipients in human medicinal products for oral use. EMA/CHMP/SWP/272921/2012, 22 October 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/11/WC500196733.pdf.
[28] Pifferi, G., Restani, P., The safety of pharmaceutical excipients. Il Farmaco 58 (2003), 541–550.
[31] International Pharmacopoeia - Six Edition, 2016 – Zidovudine oral solution; Zidovudine and lamivudine tablets; Zidovudine, lamivudine and abacavir tablets; Zidovudine, lamivudine and nevirapine tablets; Paediatric didanosine liquid for oral use; Emtricitabine and tenofovir tablets; Efavirenz, emtricitabine and tenofovir tablets; Lopinavir and ritonavir tablets; Nevirapine oral suspension. http://apps.who.int/phint/en/p/about/.
[32] Boulanger, B., Rozet, E., Moonen, F., Rudaz, S., Hubert, Ph., A risk-based analysis of the AAPS conference report on quantitative bioanalytical methods validation and implementation. J. Chromatogr. B 877 (2009), 2235–2243.
